| Revenue growth | FY26 revenue up 36% YoY to ₹503cr; Q4FY26 revenue up 35.8%. |
|---|---|
| Margins | EBITDA margins rising towards 30% target via regulated market mix. |
| Demand visibility | Strong registration pipeline in Germany, Mexico, and Colombia for growth. |
| Management confidence | Confident in meeting ₹1,000cr FY29 goal using oncology and biosimilars. |
Growth
FY26 revenue reached ₹503cr (+36% YoY); PAT grew 69% to ₹67cr; EBITDA margins expanded to 24%.
Outlook
Guided FY27 revenue of ₹650cr and PAT ₹100cr. Long-term target ₹1,000cr by FY29 with 30% EBITDA.
Risks
Geopolitical disruptions in Middle East impacting working capital cycles; regulatory delays in registration timelines for regulated markets.
Earnings Call filed with BSE, NSE: KPL. Summary written with AI assistance from the document.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,688.55
- Market cap
- ₹3,827 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 47.2×Sector 47.4×
- Promoter holding
- 54.86%-0.01% QoQ
- FII holding
- 3.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.
Kwality Pharmaceuticals Earnings Call Transcript: Key Takeaways
Kwality Pharma Q1FY27 con-call highlights revision of FY27 revenue target to ₹700Cr+ with 26-27% EBITDA margins, driven by niche injectable registrations in LATAM and MENA regions.
- Call
- Guides 30% growth
Kwality Pharmaceuticals Investor Presentation: Key Takeaways
Kwality Pharma reported strong Q1FY27 performance with revenue up 45.7% YoY. Management raised FY27 revenue guidance to INR 700+ Cr and improved margin outlook.
- Call
- Guides 39% growth
Kwality Pharmaceuticals Q1 FY27 Results: Net Profit ₹25.6 Cr, Up 115.1% YoY
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹162.4 Cr (+45.7% YoY) and net profit of ₹25.6 Cr (+115.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹25.6 Cr · +115.1% YoY
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Limited has announced the closure of its share transfer books from August 25, 2026, to August 31, 2026, for its 43rd Annual General Meeting.